With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

So I told him the Abbott Lingo and Dexcom Stelo were both good options for people who are not ... Neither company was set up for a bulk purchase, so each person had to buy their own. The price points ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Consider DexCom's performance from 2005 to 2018. DXCM Total Return Level data by YCharts. Whether it's a rebate issue or some other factor, DexCom has seen its stock price ... Stelo in the U.S ...

However, a share price moving upward ... affect blood glucose levels. The Stelo has a 15-day wear time before the sensor needs to be replaced, similar to DexCom's flagship G7 CGM, which has ...

which DexCom previously spoke about. BofA, which has a Buy rating and $90 price target on the shares, would use the stock move as a buying opportunity, as it does not see the news having an impact ...